Developer docs
API playgroundTry for free, no card

Search company profiles

Ree Labs

Full company profile

uuid000bepa

Namestring
Ree Labs
Legal namestring
ReeLabs Private Limited
Websiteurl
reelabs.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

ReeLabs Private Limited is an India-based regenerative medicine company founded in 2009 and headquartered in Mumbai, providing stem cell banking and therapy services across a broad clinical and consumer footprint. The company collects and cryopreserves stem cells from 10 different biological sources, including umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles, positioning itself as the only Indian bank with capabilities across all 10 sources. Core technology is built around proprietary processing systems (claiming 99% cell recovery) and an exclusive UK partnership with TotiCyte, which the company states delivers 2.2-3x more stem cells at the point of therapy than competing technologies. The portfolio also includes REEPLASTY (a DCGI-approved allogenic stem cell treatment for knee osteoarthritis), a patented Golden Vial anti-ageing protocol, and biological age testing through epigenetic analysis.

Short descriptiontext

ReeLabs Private Limited is an India-headquartered regenerative medicine company founded in 2009 that provides stem cell banking from 10 biological sources, stem cell therapy for 80+ disorders, the DCGI-approved REEPLASTY knee treatment, and the patented Golden Vial anti-ageing program, serving over 100,000 patients and 300+ hospitals across India and internationally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell banking, regenerative medicine, cord blood banking, stem cell therapy, biological age testing
Industry5 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAI
Bone Marrow & Stem Cell Transplant (BMT/HSCT)
NAICS code3 codes
  • Blood and Organ Banks621991
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Stem Cell Banking Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Stem Cell Banking Services
TypeSubscription Recurring
Description

One-time collection and processing fee plus recurring annual storage fees for cryopreservation of stem cells from various biological sources (cord blood, cord tissue, placenta, amniotic fluid, amniotic sac, bone marrow, adipose tissue, menstrual fluid, dental pulp). Multiple plan options with EMI payment facilities available.

reelabs.com
2Stem Cell Therapy Services
TypeOne Time License
Description

Treatment services using stem cells for over 80 approved disorders including leukemia, thalassemia, aplastic anemia, sickle cell anemia, osteoarthritis, cerebral palsy, muscular dystrophy, and others. Includes REEPLASTY knee treatment and various regenerative therapies.

reelabs.com
3Golden Vial Anti-Ageing Program
TypeProfessional Services
Description

Premium holistic biological age reversal program featuring young blood plasma and exosome administration. Customized for each individual with duration and dosage determined by doctors. Effects expected to last 5-10 years.

reelabs.com
4Biological Age Testing
TypeOne Time License
Description

Comprehensive quantifiable protocol measuring all parameters related to ageing. Samples tested at US-based CLIA certified, HIPAA compliant lab. Report delivered within 2-3 weeks.

reelabs.com
5Baby Registry Gifting Platform
TypeTransaction Fee
Description

Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1000 and multiples thereof.

reelabs.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Baby Registry Gift Contribution
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Gifting starts at ₹1000 and multiples thereof

reelabs.com
2EMI Payment Option
ModelSubscriptionBilling cadenceMonthly
Notes

EMI without interest available for middle-class customers

reelabs.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 3 records shown
1ReeVeda
Description

Range of nutraceutical products.

reelabs.com
+2 more records
Core offering1 text field

ReeLabs provides stem cell banking services from 10 different biological sources (umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles) along with stem cell therapy for over 80 approved disorders. The company also offers DCGI-approved REEPLASTY treatment for knee osteoarthritis, the patented Golden Vial anti-ageing program, and epigenetic biological age testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 2.2-3x higher stem cell recovery with TotiCyte technology
+4 more records
Product overview1 text field

Ree Labs operates as a comprehensive regenerative medicine and longevity company offering a multi-product portfolio centered on stem cell banking, therapy, and biological age assessment. The core offerings include stem cell banking services across eight tissue types (placental, umbilical cord, amniotic fluid, dental pulp, bone marrow, menstrual fluid, adipose, and cord blood via Toticyte), therapeutic applications including the DCGI-approved REEPLASTY treatment for osteoarthritis and the patented Golden Vial Anti-Ageing Program, and biological age testing via epigenetic analysis. The company extends its reach through sub-brands ReeVeda (nutraceuticals) and ReeBaby (parenting support), creating an integrated ecosystem spanning cord blood banking, anti-ageing interventions, and wellness products.

Product and service9 records
1Stem Cell Banking
CategoryStem Cell Banking
Description

Comprehensive stem cell banking services covering multiple tissue types including placental, umbilical cord, amniotic fluid and sac, dental pulp, bone marrow, menstrual fluid, and adipose tissue, with long-term cryogenic storage for future therapeutic use. Targeted at expecting and new parents and individuals seeking biological preservation.

2Stem Cell Therapy
CategoryStem Cell Therapy
Description

Therapeutic applications of stem cells for conditions including leukemia, thalassemia, osteoarthritis, cerebral palsy, and other degenerative and genetic disorders.

3REEPLASTY
CategoryRegenerative Therapy
Description

A DCGI-approved stem cell treatment for knee pain and osteoarthritis, utilizing mesenchymal stem cell (MSC) therapy to regenerate cartilage and reduce inflammation in joints. Procedure takes less than 30 minutes as outpatient treatment.

4Golden Vial Anti-Ageing Program
CategoryAnti-Ageing Therapy
Description

A patented anti-ageing protocol featuring intravenous stem cell infusions, young blood plasma and 240 types of organ-specific exosomes, interleukins, cytokines, and growth factors. Designed to combat ageing, improve vitality, and address age-related degenerative conditions. Claims to reduce biological age by up to 20 years.

5Biological Age Testing
CategoryDiagnostic Testing
Description

An epigenetic testing service that measures biological age through CpG values and DNA methylation analysis from blood samples, processed at CLIA-certified US-based laboratories to determine true cellular ageing versus chronological age. Report delivered within 2-3 weeks.

6ReeVeda
CategoryNutraceutical Products
Description

A nutraceutical product line offering science-backed nutritional supplements designed to support overall health, wellness, and cellular vitality.

7ReeBaby
CategoryBaby Care Products
Description

A comprehensive baby care product line including baby registry services and parenting support resources designed for expectant and new parents.

8Stem Cell Banking Baby Registry
CategoryFinancial Services
Description

Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1,000 and multiples thereof.

9ReeLabs Franchise Program
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1TotiCyte
Strategic tierCoreTypeTechnology or Integration
Description

Partnership with UK-based TotiCyte brings world-class cord blood processing technology to India. TotiCyte found to be highest performing cord blood processing system in peer-reviewed head-to-head study. Delivers 2.2 to 3 times more stem cells at therapy point and removes 99% of red blood cells.

reelabs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India's largest private stem cell and cord blood banking company, offering comparable umbilical cord, cord tissue, and peripheral blood banking plus community stem cell banking programmes. Direct competitor for the same expecting-parent segment in India.

TypeDirect peer
Description

US-listed cord blood bank offering private and family cord blood banking plus menstrual stem cell banking — directly comparable business model and product set to ReeLabs' 10-source banking platform.

TypeDirect peer
Description

US cord blood and cord tissue banking service owned by Revvity (formerly PerkinElmer), competing on collection quality, processing technology and storage reliability — a relevant benchmark for ReeLabs' TotiCyte-led technology story.

TypeEmerging player
Description

Clinical-stage cell therapy company developing autologous and allogeneic MSC-derived products for bone and skin regeneration. Comparable on the regenerative therapy positioning that REEPLASTY targets in orthopedics.

TypeEmerging player
Description

Bengaluru-based stem cell therapy developer focused on allogeneic MSC-based products for osteoarthritis, critical limb ischemia and other indications. Closest Indian peer on the therapy commercialisation path that ReeLabs is pursuing with REEPLASTY.

TypeEmerging player
Description

Australia-listed allogeneic MSC therapy developer with late-stage programs in inflammatory and cardiovascular indications. Comparable on the MSC-based therapy side of ReeLabs' business and a useful benchmark for therapy-stage valuations.

TypeDirect peer
Description

Cord blood and stem cell bank operating across South and Southeast Asia, offering similar cord blood and tissue banking services plus therapy access. Directly competes with ReeLabs on Indian expecting-parent customers.

TypeDirect peer
Description

Korean biotech operating one of the world's largest umbilical cord blood banks (CARTISTEM) and commercialising MSC-based stem cell therapies — combining bank + therapy model that closely mirrors ReeLabs' strategic direction.

9Global Cord Blood Corporation
TypeRegional player
Description

NYSE-listed operator of cord blood banks in China (including Hong Kong). Comparable business model (subscription cord blood storage) and regional bank network, useful as a comparable for ReeLabs' Asia footprint ambitions.

TypeDirect peer
Description

Asia-Pacific cord blood and tissue banking group with India operations, competing in the same umbilical cord banking category with similar subscription-based storage model and overlapping hospital channel partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ree Labs

Stem Cell Banking Servicesreelabs.com

ReeLabs Private Limited is an India-headquartered regenerative medicine company founded in 2009 that provides stem cell banking from 10 biological sources, stem cell therapy for 80+ disorders, the DCGI-approved REEPLASTY knee treatment, and the patented Golden Vial anti-ageing program, serving over 100,000 patients and 300+ hospitals across India and internationally.

What Ree Labs does

ReeLabs Private Limited is an India-based regenerative medicine company founded in 2009 and headquartered in Mumbai, providing stem cell banking and therapy services across a broad clinical and consumer footprint. The company collects and cryopreserves stem cells from 10 different biological sources, including umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles, positioning itself as the only Indian bank with capabilities across all 10 sources. Core technology is built around proprietary processing systems (claiming 99% cell recovery) and an exclusive UK partnership with TotiCyte, which the company states delivers 2.2-3x more stem cells at the point of therapy than competing technologies. The portfolio also includes REEPLASTY (a DCGI-approved allogenic stem cell treatment for knee osteoarthritis), a patented Golden Vial anti-ageing protocol, and biological age testing through epigenetic analysis.

Ree Labs firmographics

Firmographics
Name
Ree Labs
Legal name
ReeLabs Private Limited
Website
https://reelabs.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
ReeLabs Private Limited is an India-headquartered regenerative medicine company founded in 2009 that provides stem cell banking from 10 biological sources, stem cell therapy for 80+ disorders, the DCGI-approved REEPLASTY knee treatment, and the patented Golden Vial anti-ageing program, serving over 100,000 patients and 300+ hospitals across India and internationally.
Ownership category
akta.pro rank

Ree Labs industry classification

Industry
Product category
Stem Cell Banking Services
NAICS
Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAI
Bone Marrow & Stem Cell Transplant (BMT/HSCT)

Keywords

  • Stem cell banking
  • Regenerative medicine
  • Cord blood banking
  • Stem cell therapy
  • Biological age testing

Where Ree Labs is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices6 records

Markets served

Ree Labs business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Stem Cell Banking Services: One-time collection and processing fee plus recurring annual storage fees for cryopreservation of stem cells from various biological sources (cord blood, cord tissue, placenta, amniotic fluid, amniotic sac, bone marrow, adipose tissue, menstrual fluid, dental pulp). Multiple plan options with EMI payment facilities available.
  2. Stem Cell Therapy Services: Treatment services using stem cells for over 80 approved disorders including leukemia, thalassemia, aplastic anemia, sickle cell anemia, osteoarthritis, cerebral palsy, muscular dystrophy, and others. Includes REEPLASTY knee treatment and various regenerative therapies.
  3. Golden Vial Anti-Ageing Program: Premium holistic biological age reversal program featuring young blood plasma and exosome administration. Customized for each individual with duration and dosage determined by doctors. Effects expected to last 5-10 years.
  4. Biological Age Testing: Comprehensive quantifiable protocol measuring all parameters related to ageing. Samples tested at US-based CLIA certified, HIPAA compliant lab. Report delivered within 2-3 weeks.
  5. Baby Registry Gifting Platform: Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1000 and multiples thereof.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseBaby Registry Gift Contribution
SubscriptionMonthlyEMI Payment Option

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Ree Labs product offering

Product offering

Core offering

ReeLabs provides stem cell banking services from 10 different biological sources (umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles) along with stem cell therapy for over 80 approved disorders. The company also offers DCGI-approved REEPLASTY treatment for knee osteoarthritis, the patented Golden Vial anti-ageing program, and epigenetic biological age testing.

Product overview

Ree Labs operates as a comprehensive regenerative medicine and longevity company offering a multi-product portfolio centered on stem cell banking, therapy, and biological age assessment. The core offerings include stem cell banking services across eight tissue types (placental, umbilical cord, amniotic fluid, dental pulp, bone marrow, menstrual fluid, adipose, and cord blood via Toticyte), therapeutic applications including the DCGI-approved REEPLASTY treatment for osteoarthritis and the patented Golden Vial Anti-Ageing Program, and biological age testing via epigenetic analysis. The company extends its reach through sub-brands ReeVeda (nutraceuticals) and ReeBaby (parenting support), creating an integrated ecosystem spanning cord blood banking, anti-ageing interventions, and wellness products.

Differentiator

Problem solved

Functional benefit

Brands

  • ReeVeda: Range of nutraceutical products.
  • ReeBaby
  • Toticyte

Products and services

  • Stem Cell Banking Comprehensive stem cell banking services covering multiple tissue types including placental, umbilical cord, amniotic fluid and sac, dental pulp, bone marrow, menstrual fluid, and adipose tissue, with long-term cryogenic storage for future therapeutic use. Targeted at expecting and new parents and individuals seeking biological preservation.
  • Stem Cell Therapy Therapeutic applications of stem cells for conditions including leukemia, thalassemia, osteoarthritis, cerebral palsy, and other degenerative and genetic disorders.
  • REEPLASTY A DCGI-approved stem cell treatment for knee pain and osteoarthritis, utilizing mesenchymal stem cell (MSC) therapy to regenerate cartilage and reduce inflammation in joints. Procedure takes less than 30 minutes as outpatient treatment.
  • Golden Vial Anti-Ageing Program A patented anti-ageing protocol featuring intravenous stem cell infusions, young blood plasma and 240 types of organ-specific exosomes, interleukins, cytokines, and growth factors. Designed to combat ageing, improve vitality, and address age-related degenerative conditions. Claims to reduce biological age by up to 20 years.
  • Biological Age Testing An epigenetic testing service that measures biological age through CpG values and DNA methylation analysis from blood samples, processed at CLIA-certified US-based laboratories to determine true cellular ageing versus chronological age. Report delivered within 2-3 weeks.
  • ReeVeda A nutraceutical product line offering science-backed nutritional supplements designed to support overall health, wellness, and cellular vitality.
  • ReeBaby A comprehensive baby care product line including baby registry services and parenting support resources designed for expectant and new parents.
  • Stem Cell Banking Baby Registry Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1,000 and multiples thereof.
  • ReeLabs Franchise Program

Quantifiable outcome

  • 2.2-3x higher stem cell recovery with TotiCyte technology
  • +4 more outcomes

Companies that use Ree Labs

Customer profile

Named customers12 records

Segments5 records

Ideal customer profiles5 records

Ree Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ree Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TotiCytecoreTechnology or IntegrationPartnership with UK-based TotiCyte brings world-class cord blood processing technology to India. TotiCyte found to be highest performing cord blood processing system in peer-reviewed head-to-head study. Delivers 2.2 to 3 times more stem cells at therapy point and removes 99% of red blood cells.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Ree Labs competitors and assessment

Company assessment

Direct peers

  • LifeCell International: India's largest private stem cell and cord blood banking company, offering comparable umbilical cord, cord tissue, and peripheral blood banking plus community stem cell banking programmes. Direct competitor for the same expecting-parent segment in India.
  • Cryo-Cell International: US-listed cord blood bank offering private and family cord blood banking plus menstrual stem cell banking — directly comparable business model and product set to ReeLabs' 10-source banking platform.
  • ViaCord: US cord blood and cord tissue banking service owned by Revvity (formerly PerkinElmer), competing on collection quality, processing technology and storage reliability — a relevant benchmark for ReeLabs' TotiCyte-led technology story.
  • Cryoviva India: Cord blood and stem cell bank operating across South and Southeast Asia, offering similar cord blood and tissue banking services plus therapy access. Directly competes with ReeLabs on Indian expecting-parent customers.
  • Medipost: Korean biotech operating one of the world's largest umbilical cord blood banks (CARTISTEM) and commercialising MSC-based stem cell therapies — combining bank + therapy model that closely mirrors ReeLabs' strategic direction.
  • CordLife: Asia-Pacific cord blood and tissue banking group with India operations, competing in the same umbilical cord banking category with similar subscription-based storage model and overlapping hospital channel partnerships.

Emerging players

  • Novadip Biosciences: Clinical-stage cell therapy company developing autologous and allogeneic MSC-derived products for bone and skin regeneration. Comparable on the regenerative therapy positioning that REEPLASTY targets in orthopedics.
  • Stempeutics Research: Bengaluru-based stem cell therapy developer focused on allogeneic MSC-based products for osteoarthritis, critical limb ischemia and other indications. Closest Indian peer on the therapy commercialisation path that ReeLabs is pursuing with REEPLASTY.
  • Mesoblast: Australia-listed allogeneic MSC therapy developer with late-stage programs in inflammatory and cardiovascular indications. Comparable on the MSC-based therapy side of ReeLabs' business and a useful benchmark for therapy-stage valuations.

Regional players

  • Global Cord Blood Corporation: NYSE-listed operator of cord blood banks in China (including Hong Kong). Comparable business model (subscription cord blood storage) and regional bank network, useful as a comparable for ReeLabs' Asia footprint ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ree Labs social profiles

Digital presence

Ree Labs compliance and trust

Trust signal

Compliance7 records

Ree Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ree Labs leadership team

Management profile

Number of profiles

Profiles1 record

Ree Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ree Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ree Labs

What does Ree Labs do?

ReeLabs provides stem cell banking services from 10 different biological sources (umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles) along with stem cell therapy for over 80 approved disorders. The company also offers DCGI-approved REEPLASTY treatment for knee osteoarthritis, the patented Golden Vial anti-ageing program, and epigenetic biological age testing.

Is Ree Labs a public or private company?

Ree Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ree Labs founded?

Ree Labs was founded in 2009. It employs 101 to 250 people.

Where is Ree Labs based?

Ree Labs is headquartered in Mumbai, India, in the Asia region.

How does Ree Labs make money?

Five revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are stem Cell Therapy Services, golden Vial Anti-Ageing Program, biological Age Testing and baby Registry Gifting Platform.

Who are Ree Labs's main competitors?

Direct peers on record are LifeCell International, Cryo-Cell International, ViaCord, Cryoviva India, Medipost and CordLife. Emerging players are Novadip Biosciences, Stempeutics Research and Mesoblast. Global Cord Blood Corporation is listed as a regional player.

Does Ree Labs have an API?

No public API is recorded for Ree Labs.

What industry is Ree Labs in?

Ree Labs's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 621991 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales